Ausgabe 1/2013
Inhalt (11 Artikel)
Ibrutinib (PCI-32765), the First BTK (Bruton’s Tyrosine Kinase) Inhibitor in Clinical Trials
- Chronic Leukemias (S O’Brien, Section Editor)
Jennifer R. Brown
Lenalidomide Alone and in Combination for Chronic Lymphocytic Leukemia
- Chronic Leukemias (S O’Brien, Section Editor)
Christine I. Chen
Targeting Chronic Myeloid Leukemia Stem Cells
- Chronic Leukemias (J Goldman, Section Editor)
Ross Kinstrie, Mhairi Copland
GS-1101: A Delta-Specific PI3K Inhibitor in Chronic Lymphocytic Leukemia
- Chronic Leukemias (S O’Brien, Section Editor)
Ines M. Macias-Perez, Ian W. Flinn
Role of Epigenetics in Chronic Myeloid Leukemia
- Open Access
- Chronic Leukemias (J Goldman, Section Editor)
Katerina Machova Polakova, Jitka Koblihova, Tomas Stopka
Management of the New Patient with CML in Chronic Phase
- Chronic Leukemias (J Goldman, Section Editor)
David Marin
Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia
- Chronic Leukemias (J Goldman, Section Editor)
Jiří Pavlů, Jane F. Apperley
Monoclonal B Cell Lymphocytosis—What Does It Really Mean?
- Chronic Leukemias (S O’Brien, Section Editor)
Andy C. Rawstron
CARs in Chronic Lymphocytic Leukemia – Ready to Drive
- Chronic Leukemias (S O’Brien, Section Editor)
Chitra Hosing, Partow Kebriaei, William Wierda, Bipulendu Jena, Laurence J. N. Cooper, Elizabeth Shpall
Signal Transduction in the Chronic Leukemias: Implications for Targeted Therapies
- CHRONIC LEUKEMIAS (J GOLDMAN, SECTION EDITOR)
Wesam Ahmed, Richard A. Van Etten
What Do We Do with Chronic Lymphocytic Leukemia with 17p Deletion?
- Chronic Leukemias (S O’Brien, Section Editor)
L. Sellner, S. Denzinger, S. Dietrich, H. Glimm, O. Merkel, P. Dreger, T. Zenz